TY - JOUR
T1 - Burden of respiratory disease in Korea
T2 - An observational study on allergic rhinitis, asthma, COPD, and rhinosinusitis
AU - Yoo, Kwang Ha
AU - Ahn, Hae Ryun
AU - Park, Jae Kyoung
AU - Kim, Jong Woong
AU - Nam, Gui Hyun
AU - Hong, Soon Kwan
AU - Kim, Mee Ja
AU - Ghoshal, Aloke Gopal
AU - Muttalif, Abdul Razak Bin Abdul
AU - Lin, Horng Chyuan
AU - Thanaviratananich, Sanguansak
AU - Bagga, Shalini
AU - Faruqi, Rab
AU - Sajjan, Shiva
AU - Baidya, Santwona
AU - Wang, De Yun
AU - Cho, Sang Heon
N1 - Publisher Copyright:
© The Korean Academy of Asthma, Allergy and Clinical Immunology.
PY - 2016
Y1 - 2016
N2 - Purpose: The Asia-Pacific Burden of Respiratory Diseases (APBORD) study is a cross-sectional, observational one which has used a standard protocol to examine the disease and economic burden of allergic rhinitis (AR), asthma, chronic obstructive pulmonary disorder (COPD), and rhinosinusitis across the Asia-Pacific region. Here, we report on symptoms, healthcare resource use, work impairment, and associated costs in Korea. Methods: Consecutive participants aged ≥18 years with a primary diagnosis of asthma, AR, COPD, or rhinosinusitis were enrolled. Participants and their treating physician completed a survey detailing respiratory symptoms, healthcare resource use, and work productivity and activity impairment. Costs included direct medical cost and indirect cost associated with lost work productivity. Results: The study enrolled 999 patients. Patients were often diagnosed with multiple respiratory disorders (42.8%), with asthma/AR and AR/rhinosinusitis the most frequently diagnosed combinations. Cough or coughing up phlegm was the primary reason for the medical visit in patients with a primary diagnosis of asthma and COPD, whereas nasal symptoms (watery runny nose, blocked nose, and congestion) were the main reasons in those with AR and rhinosinusitis. The mean annual cost for patients with a respiratory disease was US$8,853 (SD 11,245) per patient. Lost productivity due to presenteeism was the biggest contributor to costs. Conclusions: Respiratory disease has a significant impact on disease burden in Korea. Treatment strategies for preventing lost work productivity could greatly reduce the economic burden of respiratory disease.
AB - Purpose: The Asia-Pacific Burden of Respiratory Diseases (APBORD) study is a cross-sectional, observational one which has used a standard protocol to examine the disease and economic burden of allergic rhinitis (AR), asthma, chronic obstructive pulmonary disorder (COPD), and rhinosinusitis across the Asia-Pacific region. Here, we report on symptoms, healthcare resource use, work impairment, and associated costs in Korea. Methods: Consecutive participants aged ≥18 years with a primary diagnosis of asthma, AR, COPD, or rhinosinusitis were enrolled. Participants and their treating physician completed a survey detailing respiratory symptoms, healthcare resource use, and work productivity and activity impairment. Costs included direct medical cost and indirect cost associated with lost work productivity. Results: The study enrolled 999 patients. Patients were often diagnosed with multiple respiratory disorders (42.8%), with asthma/AR and AR/rhinosinusitis the most frequently diagnosed combinations. Cough or coughing up phlegm was the primary reason for the medical visit in patients with a primary diagnosis of asthma and COPD, whereas nasal symptoms (watery runny nose, blocked nose, and congestion) were the main reasons in those with AR and rhinosinusitis. The mean annual cost for patients with a respiratory disease was US$8,853 (SD 11,245) per patient. Lost productivity due to presenteeism was the biggest contributor to costs. Conclusions: Respiratory disease has a significant impact on disease burden in Korea. Treatment strategies for preventing lost work productivity could greatly reduce the economic burden of respiratory disease.
KW - Cost of illness
KW - Health care costs
KW - Korea
KW - Respiratory tract disease
UR - http://www.scopus.com/inward/record.url?scp=84990829275&partnerID=8YFLogxK
U2 - 10.4168/aair.2016.8.6.527
DO - 10.4168/aair.2016.8.6.527
M3 - 文章
AN - SCOPUS:84990829275
SN - 2092-7355
VL - 8
SP - 527
EP - 534
JO - Allergy, Asthma and Immunology Research
JF - Allergy, Asthma and Immunology Research
IS - 6
ER -